An exciting update from two phase 3 clinical trials! Nerandomilast (BI 1015550) is a potential new oral antifibrotic medication. In the FIBRONEER studies of 1,117 patients with IPF and 1,176 patients with other types of progressive pulmonary fibrosis (PPF), the twice-per-day medication has been shown to slow decline in lung function over 52 weeks. "The current clinical trials represent a meaningful advancement in the treatment landscape for persons living with IPF and progressive ILD other than IPF." - Joyce Lee, MD, MS – PFF Senior Medical Advisor, Research and Health Care Quality You can read more about this exciting news at https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf (fb)

Supplemental oxygen has been part of Medicare’s competitive bidding program for the past 14 years, preventing respiratory and pulmonary patients from accessing medically necessary supplemental oxygen equipment, supplies, and services, particularly for those with high oxygen flow needs. A recent op-ed in The Well News urges Congress to pass the bipartisan Supplemental Oxygen Access Reform Act of 2025 (S.1406/H.R. 2902) to enhance patient access to supplemental oxygen treatment modalities and enable individuals with complex lung conditions to lead active, independent lives. By establishing a stable reimbursement system and improving access to respiratory therapists, more patients who depend on supplemental oxygen can receive the essential care and support they require. Read the op-ed here: https://www.thewellnews.com/in-the-news/reform-supplemental-oxygen-for-chronically-ill-patients/ (fb)